Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin..
Clin Colorectal Cancer. 15(2), 164-9.
(2016).
(2015).
The impact of oxaliplatin-based chemotherapy for colorectal cancer on the autonomous nervous system..
Eur J Neurol. 21(12), 1471-7.
(2014). Efficacy versus safety concerns for aerosol chemotherapy in non-small-cell lung cancer: a future dilemma for micro-oncology..
Future Oncol. 9(4), 505-25.
(2013). Establishing the optimal nebulization system for paclitaxel, docetaxel, cisplatin, carboplatin and gemcitabine: back to drawing the residual cup..
Int J Pharm. 453(2), 480-7.
(2013).
(2013).
(2013). Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study..
Cancer Chemother Pharmacol. 69(2), 477-84.
(2012). Evaluation of 5-methyl-2'-deoxycytidine stability in hydrolyzed and nonhydrolyzed DNA by HPLC-UV..
Bioanalysis. 4(4), 367-72.
(2012).
(2012).
(2011).
Biweekly vinorelbine and gemcitabine as second-line treatment and beyond in non-small cell lung cancer..
Chemotherapy. 56(5), 353-8.
(2010). Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial..
Ann Oncol. 20(2), 278-85.
(2009). A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study..
Breast Cancer Res Treat. 115(1), 87-99.
(2009). Weekly docetaxel with or without gemcitabine as second-line chemotherapy in paclitaxel-pretreated patients with metastatic breast cancer: a randomized phase II study conducted by the Hellenic Co-Operative Oncology Group..
Oncology. 77(3-4), 212-6.
(2009). XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis..
Curr Med Res Opin. 25(3), 797-805.
(2009).